News

Article

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%

Author(s):

Key Takeaways

  • Lupin's Loteprednol Etabonate Ophthalmic Gel, 0.38% is FDA-approved for treating postoperative ocular inflammation and pain.
  • The gel is bioequivalent to Bausch & Lomb’s Lotemax SM Ophthalmic Gel, with $29 million in annual US sales.
SHOW MORE

Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ocular inflammation and pain.

(Image Credit: AdobeStock)

(Image Credit: AdobeStock)

Lupin Limited recently announced the US Food and Drug Administration (FDA) approval for the company’s Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%.1

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid for the treatment of postoperative inflammation and pain following ocular surgery. It is the bioequivalent to Bausch & Lomb’s Lotemax SM Ophthalmic Gel. Additionally, Loteprednol Etabonate Ophthalmic Gel, 0.38% had an estimated annual sale of $29 million in the US, according to a press release.

Lupin is eligible for 180 days of drug exclusivity, as the company is the exclusive first-to-file for the product.

Reference:
  1. kw2023. Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China. Lupin. Published July 2025. Accessed July 1, 2025. https://www.lupin.com/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-gel/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
© 2025 MJH Life Sciences

All rights reserved.